OnKure Therapeutics Price to Free Cash Flow Ratio 2020-2024 | OKUR

OnKure Therapeutics price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as

OnKure Therapeutics Price to Free Cash Flow Ratio 2020-2024 | OKUR

OnKure Therapeutics price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.1B
Takeda Pharmaceutical (TAK)$44.8B
Merck (MKGAF)$21.8B
Astellas Pharma (ALPMY)$20.6B
Sandoz Group AG (SDZNY)$18.4B
Summit Therapeutics (SMMT)$17B
United Therapeutics (UTHR)$16.5B
Shionogi (SGIOY)$12.2B
Neurocrine Biosciences (NBIX)$12B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.4B
Jazz Pharmaceuticals (JAZZ)$7.1B
Ionis Pharmaceuticals (IONS)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Corcept Therapeutics (CORT)$4.9B
Crinetics Pharmaceuticals (CRNX)$4.7B
Madrigal Pharmaceuticals (MDGL)$4.7B
Dyne Therapeutics (DYN)$3.6B
PTC Therapeutics (PTCT)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$2B
Harrow (HROW)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Ocular Therapeutix (OCUL)$1.8B
NewAmsterdam Pharma (NAMS)$1.7B
ARS Pharmaceuticals (SPRY)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B